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ABSTRACT 
 
Objective: To establish the long term outcomes of risk stratified management of 
differentiated thyroid cancer (DTC). 
Background: Guidelines for management of DTC lack a strong evidence base and 
expose patients to overtreatment. This prospective study of patients diagnosed with 
DTC between 1977-2012 describes the long term outcomes of a conservative risk 
stratified (AMES) management policy . 
Methods: Outcomes were analysed around patient and tumour characteristics, 
primary intervention (surgery +/- radioiodine (RAI)), in terms of mortality, recurrence 
and reintervention. 
Results: Median follow-up in 348 patients was 14 years: mean age 48 (range 10- 
 
91) years, 257 (73.9%) female, 222 (68.3%) papillary cancer, tumour size 3.4 + 2.0 
cm (mean + SD). 89 (25.6%) AMES high risk, 116 (33.3%) TNM stage III/IV and 16 
(4.6%) had distant metastases. Primary surgery comprised lobectomy in 189 
(54.3%): 11 (5.8%) patients had subsequent completion total thyroidectomy with 
cancer present in five. Primary nodal surgery was performed in 142 (40.8%) 
patients. 35 (13.5%) low and 43 (48.3%) high risk patients received RAI following 
initial surgery. Overall disease specific survival (DSS) was 92.1% at 10 years and 
90.7% at 20 years. DSS at 20 years was 99.2% in low risk cases. AMES risk 
scoring predicted both survival and recurrence. Patients receiving RAI and AMES 
high risk were significantly associated with increased risk of death and recurrence. 
Conclusions: Routine total thyroidectomy and RAI are not justifiable for low risk 
DTC. Treatment should be tailored to risk and AMES risk stratification remains a 
simple reliable clinical tool. 
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INTRODUCTION 
 
Differentiated thyroid cancer (DTC) although rare, with a UK annual 
incidence of 4 per 100,000 population, is the commonest endocrine cancer and the 
incidence is increasing1. The British age-standardised incidence has more than 
doubled between 1975 and 2008 with a particular increase in small tumours1. The 
reasons for this increase include coincidental detection and increased population 
awareness – particularly, but not exclusively, for this group of small tumours2. 
Countries, with the most liberal access to diagnostic imaging and screening, such 
as the USA and South Korea, have the largest increase in incidence3,4. 
 
Although thyroid cancer comprises a heterogeneous range of diseases, 
including some anaplastic tumours and lymphomas, the majority are indolent. The 
two main histological types, papillary (PTC) and follicular (FTC) have differences but 
share an inherently good prognosis and long natural history5. Although there is an 
increase in high quality observational studies there is a virtual absence of 
randomised trials to properly inform surgical options; thus controversy remains 
about the optimum treatment for DTC and potential for harms from over-treatment. 
 
 
There are reports of large case series, some comprising thousands of 
patients6, from tertiary centres with an international referral base and remote long 
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term follow-up7, heterogeneous national databases8, Far Eastern centres with large 
numbers and cultural aversion to radiotherapy9, with variable primary thyroid and 
nodal surgery8, with relatively short follow-up and proxy outcomes variously 
managed by radiation oncologists10, surgeons or endocrinologists. Furthermore 
although management related to risk is now being advocated this follows inital 
radical surgery and radioactive iodine therapy11 that may represent overtreatment 
for many patients.The resulting confusion makes formulation of guidelines 
problematic. 
 
 
The Grampian region of North East Scotland is geographically remote with a 
stable population of around 500,000 and a single combined medical/surgical thyroid 
unit in the Aberdeen Royal Infirmary since the 1950s. The multidisciplinary clinic 
was the first in the UK to introduce and analyse the impact of Fine Needle 
Aspiration Cytology (FNAC) on the management of thyroid swellings12,13 and 
prospectively collected data on thyroid cancer since 1977. 
 
 
The underlying treatment philosophy was conservative avoiding 
overtreatment with both surgery and radioactive iodine (RAI). This prospective 
population based cohort study provides a perspective on the long-term outcome of 
a simple risk based approach to the management of DTC. 
 
 
METHODS 
 
This manuscript was prepared to conform to the STROBE statement on 
cohort observational studies14. 
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All patients diagnosed with thyroid malignancy in the North East of Scotland 
between January 1977 and December 2012 were entered in a customised 
database. Information on preoperative investigation, operative procedure, 
pathology, adjuvant treatment and follow-up were collected. All patients were 
routinely consented for inclusion within the database; NHSG R&D did not require 
separate ethical permission for this analysis. All pathology was reported and 
reviewed by pathologists with an interest in thyroid cancer on at least three 
occasions with problematic cases sent elsewhere for further opinions. 
 
 
Preoperative investigation evolved and included routine thyroid function, 
autoantibody status and FNAC (post 1981). Chest radiography and CT scanning 
were used selectively after FNAC or other investigation, e.g. node biopsy indicating 
DTC. Ultrasound15 and MRI16 scanning were evaluated in the 1980s and 90s and 
abandoned as routine first line investigations. After 2000 ultrasound scans were 
used to assess lymph nodes in patients scheduled for surgery for nodules 
confirmed to be, or suspicious for cancer. The minimum investigation necessary to 
formulate a treatment plan was used. 
 
 
The surgical strategy until 2000 was to remove all macroscopic disease 
including involved or suspicious lymph nodes. The majority of patients had a total 
thyroid lobectomy with bilateral near/total thyroidectomy reserved for patients with 
bilateral disease, or deemed likely to require RAI. Completion total thyroidectomy 
following a diagnostic or therapeutic lobectomy was not routine. Post 2000 all 
patients with a preoperative diagnosis of cancer underwent imaging of the lateral 
cervical nodes with ultrasound, although some already had CT, MRI and/or latterly 
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PET/CT, to permit directed compartmental nodal dissection. After 2001 diagnostic 
central compartment node sampling was carried out in patients with no other 
indication for nodal removal but abandoned with a return to selective surgery after 
201017. Limited lateral nodal surgery was defined as removal of macroscopically 
abnormal lateral lymph nodes within or comprising a single lateral level. lntra- 
operative nerve monitoring was not used. Adjuvant RAI was based on risk. Whole 
Body Scanning (WBS) carried out ten days post- administration of theraputic RAI to 
identify areas of uptake. Low dose RAI diagnostic scans were not used routinely. 
 
 
Since 2000 all cases were reviewed at an expanded multidisciplinary 
meeting (MDT) comprising endocrine surgeons, medical endocrinologists (licensed 
to administer RAI), pathologists, radiologists, ENT surgeons and medical oncologist. 
The MDT included the Highlands and Islands and Tayside regions of Scotland 
covering a population of one million although this study comprises only the North 
East cohort. 
 
 
Follow-up comprised one month postoperative, six months for two years then 
annual review thereafter. All patients received levo-thyroxine to suppress 
endogenous TSH production: serum thyroglobulin was measured at each review 
except in patients with high anti-thyroglobulin antibody titres. Re-imaging and repeat 
FNAC were carried out if a new swelling was detected on examination or 
thyroglobulin increased. Thyroglobulin can be used for follow-up in patients who 
have not undergone total thyroidectomy18. Patients were seen at a dedicated 
thyroid clinic unless they left the region when follow-up continued by postal review 
by a local specialist. 
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Sufficient information was recorded to permit risk stratification using AMES19 
high/low risk (Table 1), MACIS7 score and the sequential iterations of TNM staging, 
currently Version 720. Outcomes assessed included overall and disease specific 
survival (DSS) and recurrence stratified by primary surgery, pathological type, RAI, 
AMES risk and TNM (V7) stage. 
 
 
Statistical analysis: 
 
Categorical variables were described using number and percentage, with 
normally distributed continuous variables as mean (standard deviation, SD), or 
median and inter-quartile range (IQR) if skewed. Kaplan-Meier plots were created to 
compare survival/recurrence for primary surgery, pathological type, RAI, AMES and 
TNM stage. Cox regression was used to assess the factors influencing DSS with 
results presented as adjusted hazard ratios and 95% confidence intervals. 
 
 
RESULTS 
 
Between January 1977 and December 2012, 348 patients were diagnosed 
with DTC (Table 2). All patients were followed up to the end of 2014, 96.0% in 
Aberdeen. In terms of primary therapy the majority of patients were treated with 
lobectomy 189 (54.3%) of 348, which included 30 (33.7%) of 89 AMES high risk 
patients (Table 3). Eleven (5.8%) of 189 lobectomy patients required subsequent 
completion total thyroidectomy: 5 (2.6%) had malignancy in the second lobe. The 
majority 206 (59.2%) of patients had no nodal surgery, 87 (25.0%) having only 
central compartment or limited nodal surgery, 55 (22.4%) had lateral neck node 
dissections, RAI was given to 78 (22.4%): 46 (53.9%) AMES high risk and 35 
(13.5%) low risk patients following initial surgery. 
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With a median follow up of 14 years 75 (21.6 %) of 348 patients had died: 24 
(6.9%) of DTC. 22 (24.8%) of 89 AMES high risk and 2 (0.8%) of 259 low risk 
patients died of DTC. DSS was 92.1% at 10 years and 90.7% at 20 years. DSS was 
better following initial thyroid lobectomy (Figure 1a), absence of RAI administration 
(Figure 1b) and AMES low risk (Figure 1c). Improved DSS according to the 
individual components (age, gender, size, spread and metastases) of the AMES 
score was confirmed. A similar striking relationship between initial lobectomy, RAI 
and AMES low risk and recurrence was found (Figure 2). The expected relationship 
between DSS and recurrence according to TNM stage was also seen (Figure 3) but 
there was no difference in DSS or recurrence according to histological type (Figure 
4). Total thyroidectomy increased from 71/228 (31.0%) before 2000 to 88/120 
(73.3%) post 2000 and RAI from 41/228 (18.0%) to 52/120 (43.3%) with no 
improvement in survival (Figure 5) or recurrence. 
 
 
The results of multivariate analyses are shown in Table 4. Administration of 
RAI and AMES high risk were statistically associated with significantly increased 
risk of DTC death. The risk of recurrence was related to whether the patient had a 
total thyroidectomy and AMES high risk. MACIS scores were calculated 
retrospectively for all patients and prospectively for those diagnosed after 2010 and 
conformed to the risk groups described, 
 
 
DISCUSSION 
 
This prospective study with long term (mean follow up 14 years) outcomes 
following treatment of DTC in the UK and is based on a stable population in an 
isolated geographic region with complete follow-up. There has been a combined 
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medical/surgical thyroid clinic throughout with a commitment to evaluation of 
process and outcomes in thyroid cancer. We were the first in the UK to introduce 
and systematically analyse the impact of fine needle aspiration cytology (FNAC) on 
the management of thyroid swellings.12,13 Studies of imaging modalities including 
ultrasound15 and MRI16 scanning also influenced the development of efficient local 
protocols. 
 
 
Of particular relevance has been a consistently conservative approach to the 
management of DTC. Although this evolved and became more explicit over the 35 
years of patient recruitment, the underlying philosophy was to tailor treatment to 
risk. Initially the surgical approach was to remove all macroscopic disease with total 
thyroidectomy reserved for bilateral disease, high risk tumours and adjuvant RAI 
likely to be required. Following the publication of the first British Association of 
Endocrine Surgeons guidelines diagnostic central compartment node sampling, with 
preservation of the thymus where possible and without skeletonisation of the 
recurrent nerves, was carried out in patients with no clinical or radiological evidence 
of nodal involvement. We reverted to selective dissection based on clinical 
assessment at operation after 8 years.17 Lateral neck dissections became more 
frequent with levels resected guided by imaging. Frozen section was used intra- 
operatively to assess questionable nodal involvement. Completion total 
thyroidectomy was not routine following thyroid lobectomy (Table 3) and TSH was 
routinely suppressed. Decisions around treatment were made amongst a group 
comprising surgeons, endocrinologists (responsible for RAI administration) and 
pathologists until the larger MDT was established in 2000 when ENT surgeons, 
radiologists and oncologists also contributed. Indications for more radical therapy 
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including RAI and (completion) total thyroidectomy were influenced by adverse 
pathological features. Follow-up was six monthly for two years then annually 
thereafter following any surgical procedure. Review comprised examination, 
measurement of serum TSH, free T3 and T4, and thyroglobulin. Any new 
symptoms, clinical findings or rise in thyroglobulin triggered further investigation.18 
Elimination of serum thyroglobulin was not a therapeutic objective and a stable (low) 
serum thyroglobulin was accepted. Patients with serum antithyroglobulin antibodies 
were managed on an individual basis depending on risk. 
 
 
Weaknesses of this study include the relatively small population studied, the 
number of new cancers diagnosed annually and, some will argue, not using 
ultrasound as a first line investigation. The incidence of DTC in Grampian is the 
second lowest in Scotland21 and it can be argued that our practice is missing occult 
and minimal cancers by not carrying out routine ultrasound, total thyroidectomy and 
more extensive prophylactic nodal surgery22. These criticisms are valid only if such 
tumours were of clinical significance. The reduction in operation rate in thyroid 
swellings which followed the introduction of FNAC12,13 has been sustained over the 
years with no evidence of late presentation of “missed” cancers23. Similarly failure to 
detect occult disease in the contralateral lobe following lobectomy, in 
macroscopically normal lymph nodes and distant metastases because prophylactic 
node dissection and WBS were not used should result in excessively high 
recurrence rates. This has not happened over the time scale of this study. 
Furthermore the cohort of patients managed prior to 1977 and not included in the 
prospective study has been followed up to death in the same clinic with no evidence 
to support this hypothesis. Therefore, internal study control negates these possible 
arguments. 
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TSH suppression has conventionally been used to reduce the risk of 
recurrence, particularly in PTC. Routine complete suppression is associated with 
potential for adverse cardiovascular outcomes (increased left ventricular mass, 
tachycardia atrial fibrillation) and osteoporosis24 and there is now evidence that this 
is unnecessary in low risk cases25. Without a clear contraindication, routine 
suppression was carried out, and it may be that this practice makes a rise in serum 
thyroglobulin more meaningful. We do not have data to comment on possible 
increased cardiac or bone issues related to this policy: it may be timely to review 
this policy for low risk patients although it will be many years before any change in 
outcome would be become apparent. 
 
 
Patients requiring RAI had a WBS ten days post therapy with subsequent 
doses tailored to uptake, response and thyroglobulin level. Although the proportion 
of patients receiving RAI increased over time it has remained low compared to most 
Western guidelines. It would be virtually impossible to improve upon the excellent 
outcome in terms of both survival and recurrence observed in those not receiving 
RAI (Figure 1b & 2b) with more liberal use. 
 
 
The proportion of FTC (36.2%) in this cohort is higher than normally reported 
but consistent with an earlier comparative study in 197726. The histology was 
reviewed on at least three occasions: initially by a pathologist with a thyroid interest, 
on review at a clinico-pathological conference or MDT and subsequently as part of a 
comprehensive review of all DTC. When there was debate about classification, 
opinions were obtained from nationally recognised thyroid pathologists. A number of 
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cancers were reclassified as follicular variant of PTC as diagnostic criteria evolved. 
The high proportion of FTC was consistent with four other UK university teaching 
hospital datasets which reported a range of 20.7 -31.1% FTC27. This indicates a 
different pattern of DTC distribution in the UK, within specialist units, compared to 
other locations. 
 
 
The reliability of the AMES classification in identifying patients at risk of dying 
of DTC is confirmed beyond doubt (Figure 1c). It is notable that the cut-off point in 
terms of size in AMES is 5cm whereas much contemporary debate is around 1- 
2cm. Two AMES “low risk” patients died: Male, 35 years diagnosed in the 1980’s 
with an 8cm minimal follicular cancer treated by lobectomy presented with cerebral 
metastatic disease 14 years later which was treated by completion thyroidectomy 
and RAI but died 15 years after diagnosis: Female, 60 years 3.5cm histologically 
aggressive papillary cancer treated with total thyroidectomy and RAI but developed 
early local recurrence and metastases and died 9 years after diagnosis. Both these 
patients had features which increase perception of risk and the first patient would 
now also be treated with immediate total thyroidectomy and RAI as was the second. 
Whether this would have influenced the outcome is speculative. There is compelling 
evidence that mortality is related to the biological aggression of the tumour as 
exhibited in DNA ploidy28,29 regardless of therapy.  Although AMES risk was 
devised to determine mortality it also proved a reliable indicator of the risk of 
recurrence (Figure 2c). 
 
 
Contrary to the influential paper by Mazzaferri8 thyroid lobectomy was not 
associated with worse outcomes than total thyroidectomy. In fact the converse was 
demonstrated (Figure 1a & 2a). Mazzaferri’s paper derived from a heterogeneous 
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national dataset from a mixture of specialist and non-specialist centres and 
surgeons with no risk stratification recorded or applied. The excellent outcomes in 
this series following lobectomy alone reflect correct case stratification for low risk of 
death and, as it transpired, of recurrence. This is entirely consistent with other 
series reporting a large experience of lobectomy alone for low risk tumours10,30,31. 
By converse, there is no implication that total thyroidectomy affords an increased 
risk of poor outcome - simply that biologically aggressive disease was treated 
maximally, whilst those avoiding maximal treatment came to no harm. 
 
 
It is very striking that a similar effect is apparent in relation to the use of RAI 
(Figure 1b & 2b). Whilst our use of RAI has increased over the years, particularly in 
patients with TNM Stage III disease (age > 45 years, N1, M0), it remains at a low 
level and much less than contemporary guidelines and many publications advocate. 
There is no evidence from the HiLo trial32 that routine RAI influences even short 
term proxy outcomes in low risk cases and we predict the current IoN trial33 
comparing none with low dose RAI in low risk cases will show a similar lack of 
effect. 
 
 
We calculated MACIS scores for patients but since this depends on 
knowledge of the histology of the tumour it was not a useful tool for deciding 
operative strategy. It is a reliable indicator of long-term risk but as a continuous 
scale rather than a binary value there is more potential for debate in decision 
making. Categorical analysis produced similar results to those for TNM staging 
(Figure 3). 
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The overall and TNM stage related outcomes in terms of survival are 
comparable to all series with similar long-term follow-up despite the conservative 
treatment policy. The adverse outcomes observed following total thyroidectomy and 
RAI are not the consequence of more radical surgery or adjuvant RAI but statistical 
constructs, reflecting that patients at higher risk received more aggressive therapy. 
The virtual absence of DTC related death or recurrence in patients deemed at low 
risk and not undergoing total thyroidectomy or receiving RAI validates the treatment 
policy based on individual risk. The level of risk is easily estimated from simple 
parameters known at the time of primary surgery7. More extensive thyroid resection 
and prophylactic nodal dissection may disclose other foci of DTC but the clinical 
relevance of such incidental disease is inconsequential, consistent with autopsy 
studies demonstrating population prevalence of over 30% in asymptomatic 
individuals34. Much depends on the confidence of the MDT making these decisions: 
lack of exposure to the long-term outcomes of a conservative policy and adherence 
to guidelines with a poverty of evidence leads to over-treatment. 
 
 
Over-treatment of DTC is increasingly recognised as both financially and 
clinically detrimental35. Medical bankruptcy in the USA is 3.5 times more likely with 
thyroid than other cancers36 and many patients could be spared the cost of 
excessive surgery, RAI and imaging by recognising the benign nature of their DTC. 
This is particularly relevant in view of the dramatic increase in the rate of diagnosis 
of low risk DTC cancer over the last two decades2,37. The disadvantages of total 
thyroidectomy over lobectomy are the doubling of the risk of nerve injury, to both 
recurrent and superior laryngeal nerves, voice change and hypoparathyroidism. 
Although there are many selected series reporting extremely low rates of these 
complications following routine total thyroidectomy these are not representative of 
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unselected results reported in national registries38 even amongst high volume 
surgeons39. 
 
Of concern is the potential for long-term effects of therapeutic RAI; apart from 
acute inflammation in salivary glands due to high uptake. There is a higher rate of 
malignancy in salivary gland, bowel and bone marrow amongst patients treated with 
RAI40. Whilst this association may be serendipitous the possibility exists that a 
second potentially more lethal malignancy may be induced by a high dose of 
radiation administered unnecessarily for a tumour with a negligible risk of death. 
This is especially relevant when the patient is young. Even if the second malignancy 
is not caused by RAI there is a cogent argument for avoiding unnecessary 
irradiation to patients with an apparent increased predisposition to develop cancer 
compared to the normal population. 
 
 
Elimination of serum thyroglobulin as a therapeutic objective and proxy for 
long-term survival is problematic for a number of reasons. In many centres 
detectable thyroglobulin is considered to represent recurrence and Increasingly 
sensitive assays lower the threshold for such detection, When this initiates a search 
for recurrence occult disease may be found or suspected with the potential for 
further, more risky surgery and which may not impact on survival or clinically 
relevant recurrence. Only one third of tissue resected for such ‘recurrence’ is 
subsequently histologically confirmed41 - the concept of overtreatment may apply 
beyond that of the primary intervention. 
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The uncertainty around recommendations for optimal management for low 
risk cancers remains manifest in guidelines; the 2014 British Thyroid Association 
guidelines state “ The evidence for an advantage of total thyroidectomy compared 
to hemithyroidectomy in patients with unifocal tumours >1– ≤4 cm in diameter, age 
<45 years, with no extrathyroidal spread, no familial disease, no evidence of lymph 
node involvement, no angioinvasion and no distant metastases, is unclear”42. This 
study clarifies the position. The AMES criteria for defining risk may appear liberal to 
practitioners accustomed to a policy of total thyroidectomy and RAI for all but are 
justified not only in terms of mortality but also, and previously unreported, 
recurrence. The debate on the optimal management of DTC will continue but the 
movement away from routine aggressive multimodal therapy for all DTC manifest in 
early guidelines is already clear43 and will continue. In practical terms no patient 
with papillary thyroid cancer selected to receive only thyroid lobectomy and no RAI 
died of thyroid cancer. Simple clinical risk stratification based on information 
available at the time of the primary surgery avoided the cost and complications of 
overtreatment in many patients with no demonstrable detriment over 37 years of 
this study. Radical surgery and adjuvant RAI therapy based on the risk of death and 
recurrence can be restricted to those at higher risk with the proviso that neither of 
these major outcomes may be affected in those with the most aggressive cancers. 
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TABLE LEGENDS 
 
Table 1: AMES risk stratification adapted from Cady et al Cancer 1979 
 
 
Table 2: Demography, pathology, risk and stage in 348 patients 
 
 
Table 3: Primary management of 348 DTC patients 1977-2014 
 
 
Table 4:Multivariate analysis 
 
 
FIGURE LEGENDS 
 
Figure 1: Kaplan-Meier plots of DSS according to primary surgical procedure, 
administration of RAI and AMES Risk 
 
 
Figure 2: Kaplan-Meier plots of recurrence according to primary surgical procedure, 
administration of RAI and AMES Risk 
 
 
Figure 3: Kaplan-Meier plots of DSS, recurrence and TNM stage 
 
 
Figure 4: Kaplan-Meier plots of DSS, recurrence and histological type 
 
 
Figure 5: Kaplan-Meier plots of DSS according to TNM stage before or after 2000. 
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Table 1 
 
HIGH risk LOW risk 
Male age >40 years All other patients 
Female age >50 years  
and tumour size > 5cm  
or extrathyroidal spread  
or distant metastases  
 Table 
 
 
 
 
 
Table 2 
 
Gender male 91 26.1% 
 female 257 73.9% 
Age (years) mean 48  
 range 10 - 91  
Follow-up (years) mean 13.0  
 range 2 - 37  
Pathology mean size 3.4 cm  
Papillary  222 63.8% 
 mPTC 32 9.2% 
Follicular  126 36.2% 
 mFTC 71 20.4% 
AMES risk High 89 25.6% 
 Low 259 74.4% 
TNM stage I 181 52.0% 
 II 51 14.7% 
 III 64 18.4% 
 IV 52 14.9% 
mPTC: micropapillary thyroid cancer <1 cm 
mFTC: minimal follicular thyroid cancer 
 Table 
 
 
 
 
 
Table 3 
 
AMES Low Risk High Risk Total 
 259 89 348 
First operation    
Lobectomy 159 61.4% 30 33.7% 189 54.3% 
Subsequent completion 8 3 +ve 3 2 +ve 11 5 +ve 
Total thyroidectomy 100 38.6% 59 66.3% 159 45.7% 
Nodal surgery       
none 157 60.6% 49 55.1% 206 59.2% 
central / limited 62 23.9% 25 28.1% 87 25.0% 
lateral neck 40 15.4% 15 16.9% 55 15.8% 
       
Radio-active iodine 35 13.5% 43 48.3% 78 22.4% 
+ve: malignancy present in second lobectomy specimen 
 Table 
 
 
 
 
 
Table 4 
 
Disease specific survival 
 Hazard 
Ratio 
Adjusted 
Hazard Ratio 
95% 
confidence interval 
p 
Histology PTC 0.8 1.1 0.40 – 3.26 0.81 
RAI - any 18.9 6.3 1.81 – 21.61 0.004 
Total thyroidectomy 3.3 0.6 0.19 – 1.57 0.27 
AMES High Risk 41.8 22.0 4.65 – 103.60 <0.001 
Nodal Surgery (major) 2.8 2.1 0.53 – 8.48 0.29 
 
Recurrence 
Histology PTC 1.0 2.6 1.1 – 5.9 0.03 
RAI - primary 7.1 1.6 0.79 – 3.38 0.19 
Total thyroidectomy 7.2 4.2 3.29 – 13.30 <0.001 
AMES High Risk 10.4 6.6 1.76 – 10.22 <0.001 
Nodal Surgery (major) 3.6 3.0 1.11 – 8.09 0.03 
  
  
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
FIGURE LEGENDS 
 
 
Figure 1: Kaplan-Meier plots of Disease Specific Survival (DSS) according to 
a: primary surgical procedure 
b: administration of RAI 
c: AMES Risk 
 
 
Figure 2: Kaplan-Meier plots of Recurrence according to 
a: primary surgical procedure 
b: administration of RAI 
c: AMES Risk 
 
 
Figure 3: Kaplan-Meier plots of DSS, Recurrence and TNM stage 
 
 
Figure 4: Kaplan-Meier plots of DSS, Recurrence and histological type 
 
 
Figure 5: Kaplan-Meier plots of DSS according to TNM stage before or after 
2000. 
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